Telomir Pharmaceuticals, Inc. (TELO): Total Liabilities
$1.43M
As of 2025-12-31
$332.4K
As of 2026-06-30
+13.1%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.43M | +109.7% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $681.0K | -49.0% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $1.34M | +35.5% | 2025-02-04, Balance as of period end |
| 2022-12-31 | $986.0K | n/a | 2024-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | 2025-12-31 | $1.43M | +109.7% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $4.57M | +106.0% |
| Matinas BioPharma Holdings, Inc. (MTNB) | 2025-12-31 | $2.38M | -52.9% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $11.38M | +12.4% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $1.45M | +74.2% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $1.30M | -45.3% |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | $37.17M | +21.3% |
| Acurx Pharmaceuticals, Inc. (ACXP) | 2025-12-31 | $2.42M | -25.3% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $5.49M | -10.4% |
Compare TELO, ENSC, MTNB, ONCY side by side · Screen every company in Pharmaceutical Preparations ↗